Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
23 hedge funds and large institutions have $2.1M invested in Cyclo Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
207% more capital invested
Capital invested by funds: $683K → $2.1M (+$1.41M)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
35% more funds holding
Funds holding: 17 → 23 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFVM
Founders Fund V Management
San Francisco,
California
|
+$613K |
| 2 |
FFVM
Founders Fund VI Management
San Francisco,
California
|
+$140K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$93.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$65.7K |
| 5 |
BlackRock
New York
|
+$61.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$15K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.81K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.14K |
| 4 |
JP Morgan Chase
New York
|
-$283 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$125 |
CYTH Hedge Fund Activity: Q4 2023 in Review
23 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q4 2023, worth a combined $2.1M — up 207% from $683K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CYTH positions and 3 closed out — a net gain of 6 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Founders Fund V Management, opening a new position worth an estimated $613K. The largest seller was Virtu Financial, exiting entirely with an estimated $15K sold.
- 23 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q4 2023, up from 17 in Q3 2023.
- Funds reported $2.1M of Cyclo Therapeutics, Inc. Common Stock stock for Q4 2023, up 207% quarter-over-quarter.
- 9 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of +6 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q4 2023 was Founders Fund V Management, an estimated $613K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q4 2023 was Virtu Financial, an estimated $15K sold.
Based on aggregated 13F filings for Q4 2023.